The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphomaThe BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of <i>MYC</i>+/<i>BCL2</i>+ double hit lymphoma, Published online: 22 January 2018; doi:10.1038/s41388-017-0111-1The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Source: Oncogene - January 22, 2018 Category: Cancer & Oncology Authors: A. Esteve-Arenys J. G. Valero A. Chamorro-Jorganes D. Gonzalez V. Rodriguez I. Dlouhy I. Salaverria E. Campo D. Colomer A. Martinez G. Rymkiewicz P. P érez-Galán A. Lopez-Guillermo G. Rou é Source Type: research